Investor’s Alert: PPL Corporation (PPL), Carnival Corporation (CCL), Amgen Inc. (AMGN)

PPL Corporation (PPL) continued its upward trend with the stock climbing 0.68% or $0.24 to close the day at $35.72 on lower than average trading volume of 2.69M shares, compared to its three month average trading volume of 3.57M. The Allentown Pennsylvania 18101 based company has been outperforming the electric utilities companies by 8.6466% for last three months and its recent gains have pushed the stock slightly up 4.9% YTD, versus the electric utilities industry which is up 2.34% for the same period. The RSI of 63.05 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

PPL Corporation, a utility company, delivers electricity and natural gas in the United States and the United Kingdom. It serves 322,000 natural gas and 403,000 electric customers in Louisville and adjacent areas in Kentucky; 543,000 customers in central, southeastern, and western Kentucky; and approximately 28,000 customers in 5 counties in southwestern Virginia, and fewer than 10 customers in Tennessee. The company also provides electric delivery services to approximately 1.4 million customers in Pennsylvania; and operates 4 electricity distribution networks in the United Kingdom, as well as delivers natural gas to customers in Kentucky; generates electricity from power plants in Kentucky; and sells wholesale electricity to 11 municipalities in Kentucky. In addition, it provides finance for the operations of PPL and subsidiaries. PPL Corporation was founded in 1920 and is headquartered in Allentown, Pennsylvania.

Carnival Corporation (CCL) had a light trading with around 2.67M shares changing hands compared to its three month average trading volume of 3.32M. The stock traded between $55.7 and $56.46 before closing at the price of $56.03 with -0.8% change on the day. The Miami Florida 33178 based company is currently trading 32.35% above its 52 week low of $42.84 and -3.05% below its 52 week high of $57.79. Both the RSI indicator and target price of 60.91 and $57.36 respectively, lead us to believe that it should be put on hold over the coming weeks.

Carnival Corporation operates as a leisure travel and cruise company in North America, Europe, Australia, and Asia. It offers cruises under the Carnival Cruise Line, Princess Cruises, Holland America Line, and Seabourn brands in North America; and Costa, AIDA, P&O Cruises (UK), Cunard, and P&O Cruises (Australia) brands in Europe, Australia, and Asia. The company operates approximately 100 cruise ships. It also owns Holland America Princess Alaska Tours, a tour company in Alaska and the Canadian Yukon, which owns and operates hotels, lodges, glass-domed railcars, and motor coaches. In addition, the company is involved in the leasing of cruise ships. It sells its cruises primarily through travel agents and tour operators. The company was incorporated in 1972 and is headquartered in Miami, Florida. Carnival Corporation is a subsidiary of Carnival Corporation & Plc.

Amgen Inc. (AMGN) traded within a range of $170.3 to $172.17 after opening the day at $171.56. The company has seen its stock increase in value by 18.53% so far this year. The stock was up close to 0.19% on light volume in last trading session and closed at $172.11 per share. After the recent gain, the stock is currently holding -1.35% below its 52 week high of $176.85 and 30.55% above its 12-month low of $133.64. The shares are up by over 17.84% in the last three months, and the RSI indicator value of 76.87 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company’s other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

 

Stocks Trending Alert: Amgen Inc. (AMGN), State Street Corporation (STT), Ameriprise Financial, Inc. (AMP)

Amgen Inc. (AMGN) saw its value increase by 0.23% as the stock gained $0.39 to finish the day at a closing price of $168.05. The stock was lighter in trading and has fluctuated between $133.64-$176.85 per share for the past year. The shares, which traded within a range of $165.57 to $168.07 during the day, are up by 14.3% in the past three months and down by -2.42% over the past six months. It is currently trading 6.04% above its 20 day moving average and 10.45% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $182.88 a share over the next twelve months. The current relative strength index (RSI) reading is 72.06.The technical indicator do not lead us to believe the stock will see more gains any time soon.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

State Street Corporation (STT) shares were up in last trading by 2.72% to $81.45. It experienced higher than average volume on day. The stock increased in value by almost 5.1% over the past week and fell -1.78% in the past month. It is currently trading 3.08% above its 50 day moving average and 18.57% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -2.44% decrease in value from its one year high of $83.49. The RSI indicator value of 63.88, lead us to believe that it is a hold for now.

State Street Corporation, through its subsidiaries, provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, including custody; product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; cash management; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics. It also provides investment management services, such as investment management, investment research, and investment advisory services to corporations, public funds, and other sophisticated investors, as well as offers active and passive asset management strategies across equity, fixed-income, and cash asset classes. The company offers its products and services to mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1792 and is headquartered in Boston, Massachusetts.

Ameriprise Financial, Inc. (AMP) traded within a range of $125.57 to $128.38 after opening the day at $125.58. The company has seen its stock increase in value by 15.92% so far this year. The stock was up close to 1.32% on active volume in last trading session and closed at $127.81 per share. After the recent gain, the stock is currently holding 0.73% above its 52 week high of $128.38 and 63.95% above its 12-month low of $80.39. The shares are up by over 16.02% in the last three months, and the RSI indicator value of 74.4 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Ameriprise Financial, Inc., through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The company’s Advice & Wealth Management segment provides financial planning and advice, as well as full-service brokerage services primarily to retail clients through its advisors. Its Asset Management segment offers investment management and advice, and investment products to retail, high net worth, and institutional clients through unaffiliated third party financial institutions and institutional sales force. This segment’s products include U.S. mutual funds and their non-U.S. equivalents, exchange-traded funds, variable product funds underlying insurance, and annuity separate accounts; and institutional asset management products, such as traditional asset classes, separately managed accounts, individually managed accounts, collateralized loan obligations, hedge funds, collective funds, and property funds. The company’s Annuities segment provides variable and fixed annuity products to individual clients through affiliated and unaffiliated advisors, and financial institutions. Its Protection segment offers various products to address the protection and risk management needs of retail clients, including life, disability income, and property casualty insurance through advisors and affinity relationships. The company was formerly known as American Express Financial Corporation and changed its name to Ameriprise Financial, Inc. in September 2005. Ameriprise Financial, Inc. was founded in 1894 and is headquartered in Minneapolis, Minnesota.

 

3 Trending Stocks: Amgen Inc. (AMGN), International Business Machines Corporation (IBM), Lennar Corporation (LEN)

Amgen Inc. (AMGN) managed to rebound with the stock climbing 0.25% or $0.42 to close the day at $167.89 on light trading volume of 2.93M shares, compared to its three month average trading volume of 3.76M. The Thousand Oaks California 91320 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 20.97%, compared to the industry which has dropped -0.81% over the same period. With RSI of 70.99, the stock should still continue to rise and get closer to its one year target estimate of $182.88, making it a hold for now.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

International Business Machines Corporation (IBM) climbed 0.83% during last trading as the stock added $1.47 to finish the day at $178.68 with about 2.93M shares changing hands, compared to its three month average trading volume of 3.73M. The $168.5B market cap company, which fluctuated between $176.76 and $178.87 during the day, currently situated 58.31% above its 52 week low of $121.34 and 0.47% away from its one year high of $179.25. The RSI of 70.79 indicates the stock is overbought at the current levels, sell for now.

International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure services, such as IT outsourcing, integrated technology, cloud, and technology support services. Its Global Business Services segment offers consulting and systems integration services for strategy and transformation, application innovation services, enterprise applications, and analytics; application management, maintenance, and support services; and processing platforms and business process outsourcing services. The company’s Software segment provides middleware and operating systems software, including WebSphere software to integrate and manage business processes; information management software that enables clients to integrate, manage, and analyze data from various sources; Tivoli software that manages business infrastructure in real time; Workforce Solutions, which enables businesses to connect people and processes; and Rational software that supports software development. This segment also provides Watson software to interact in natural language, process big data, and learn from interactions with people and computers; Watson Health that offers data analytics and insights of individual health; and Watson Internet of Things that allows direct sensing and communication of data. Its Systems Hardware segment offers infrastructure technologies, such as servers for businesses, organizations, and technical computing applications; and data storage products and solutions. The company’s Global Financing segment provides lease and loan financing; commercial financing to suppliers, distributors, and remarketers; and remanufacturing and remarketing services. The company was formerly known as Computing-Tabulating-Recording Co. and changed its name to International Business Machines Corporation in 1924. The company was founded in 1910 and is headquartered in Armonk, New York.

Lennar Corporation (LEN) saw its value increase by 3.58% as the stock gained $1.62 to finish the day at a closing price of $46.81. The stock was higher in trading and has fluctuated between $39.5-$49.6 per share for the past year. The shares, which traded within a range of $45.69 to $46.97 during the day, are up by 13.99% in the past three months and down by -0.56% over the past six months. It is currently trading 4.12% above its 20 day moving average and 6.14% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $0 a share over the next twelve months. The current relative strength index (RSI) reading is 63.67. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Lennar Corporation, together with its subsidiaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Lennar Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily include the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, as well as the purchase, development, and sale of residential land. The company also offers real estate related financial services, including mortgage financing, title insurance, and closing services for home buyers and others, as well as personal lines, property, and casualty insurance products. In addition, it is involved in raising, investing, and managing third party capital; and originating and selling into securitizations commercial mortgage loans, as well as investing in real estate related mortgage loans, properties, and related securities. Further, the company sponsors, invests, and manages private equity vehicles, and provides asset management and other services to the vehicles and other third parties. Additionally, the company develops multifamily rental properties. Lennar Corporation was founded in 1954 and is based in Miami, Florida.

 

Trader Alert: Amgen Inc. (AMGN), GGP Inc. (GGP), Sysco Corporation (SYY)

Amgen Inc. (AMGN) grew with the stock adding 0.78% or $1.3 to close at $168.12 on light trading volume of 3.47M compared its three months average trading volume of 3.87M. The Thousand Oaks California 91320 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 20.53% up for the period and up by 14.99% so far this year. With price target of $182.53 and a 26.65% rebound from 52-week low, Amgen Inc. has plenty of upside potential, making it a hold with a view buy.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

GGP Inc. (GGP) gained $0.24 to close the day at a new closing price of $25.05, a 0.97% increase in value from its previous closing price that moved the stock 5.38% above its 52 week low of $23.77. A total of 3.47M shares exchanged hands during the day compared with its three month average trading volume of 4.46M. The stock, which fluctuated between $24.84 and $25.18 during the day, currently situated -21.96% below its 52 week high. The stock is down by -1.96% in the past one month and down by -0.52% over the past three months. With a one year target estimate of $30.09 and RSI of 49.5, the stock still has upside potential, making it a hold for now.

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.

Sysco Corporation (SYY) shares were down in last trading by -0.77% to $51.83. It experienced lighter than average volume on day. The stock decreased in value by almost -0.42% over the past week and fell -6.91% in the past month. It is currently trading -4.5% below its 50 day moving average and 2.14% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -8.63% decrease in value from its one year high of $57.07. The RSI indicator value of 37, lead us to believe that it is a hold for now.

Sysco Corporation, through its subsidiaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry in the United States, Bahamas, Canada, Ireland, Costa Rica, and Mexico. It operates through Broadline, SYGMA, and Other segments. The company distributes a line of frozen foods, such as meats, seafood, fully prepared entrees, fruits, vegetables, and desserts; a line of canned and dry foods; fresh meats and seafood; dairy products; beverage products; imported specialties; and fresh produce. It also supplies various non-food items, including paper products comprising disposable napkins, plates, and cups; tableware consisting of China and silverware; cookware consisting of pots, pans, and utensils; restaurant and kitchen equipment and supplies; and cleaning supplies. In addition, the company offers specialty meat products, such as custom-cut fresh steaks, other meat, and poultry products; and lodging industry products, including personal care guest amenities, equipment, housekeeping supplies, room accessories, and textiles. It serves restaurants, hospitals and nursing homes, schools and colleges, hotels and motels, industrial caterers, and other foodservice venues through 200 distribution facilities. The company was founded in 1969 and is headquartered in Houston, Texas.

 

Equities Trend Analysis: Computer Sciences Corporation (CSC), Amgen Inc. (AMGN), Synchrony Financial (SYF)

Computer Sciences Corporation (CSC) grew with the stock adding 2.04% or $1.43 to close at $71.38 on active trading volume of 4.42M compared its three months average trading volume of 1.83M. The Tysons Virginia 22102 based company operating under the Information Technology Services industry has been trending up for the last 52 weeks, with the shares price now 129.44% up for the period and up by 20.13% so far this year. With price target of $66.92 and a 197.7% rebound from 52-week low, Computer Sciences Corporation has plenty of upside potential, making it a hold with a view buy.

Computer Sciences Corporation, together with its subsidiaries, provides information technology services and solutions primarily in North America, Europe, Asia, and Australia. It operates through two segments, Global Business Services (GBS) and Global Infrastructure Services (GIS). The GBS segment offers technology solutions comprising consulting, applications services, and software. This segment also provides applications services, which optimize and modernize clients’ business and technical environments that enable clients to capitalize on emerging services, such as cloud, mobility, and big data within new commercial models, including the ‘as a Service’ and digital economies; consulting services, which help organizations innovate, transform, and create sustainable competitive advantage; and vertically aligned software solutions and process-based intellectual property power mission-critical transaction engines in insurance, banking, healthcare and life sciences, manufacturing, and other diversified industries. The GIS segment offers managed and virtual desktop, unified communications and collaboration, data center management, cyber security, and compute and managed storage solutions to commercial clients. This segment also provides next-generation cloud offerings consisting of Infrastructure as a Service, private cloud solutions, CloudMail, and Storage as a Service. The company has a strategic partnership with HCL Technologies to create an applications modernization delivery network. Computer Sciences Corporation was founded in 1959 and is headquartered in Tysons, Virginia.

Amgen Inc. (AMGN) had a active trading with around 4.37M shares changing hands compared to its three month average trading volume of 3.91M. The stock traded between $165.13 and $166.89 before closing at the price of $166.58 with -0.57% change on the day. The Thousand Oaks California 91320 based company is currently trading 25.49% above its 52 week low of $133.64 and -5.17% below its 52 week high of $176.85. Both the RSI indicator and target price of  and $182.53 respectively, lead us to believe that it could rise over the coming weeks.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Synchrony Financial (SYF) saw its value decrease by -0.16% as the stock dropped $-0.06 to finish the day at a closing price of $36.45. The stock was lighter in trading and has fluctuated between $23.25-$38.06 per share for the past year. The shares, which traded within a range of $36.16 to $36.55 during the day, are up by 30.05% in the past three months and up by 30.84% over the past six months. It is currently trading 0.98% above its 20 day moving average and 1.37% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $42.82 a share over the next twelve months. The current relative strength index (RSI) reading is 53.53.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Synchrony Financial operates as a consumer financial services company in the United States. The company offers private label credit cards, dual cards, and small and medium-sized business credit products; and promotional financing for consumer purchases, such as private label credit cards and installment loans. It also provides promotional financing to consumers for elective healthcare procedures or services, such as dental, veterinary, cosmetic, vision, and audiology; debt cancellation products; and deposit products, including certificates of deposit, individual retirement, money market, and savings accounts, as well as accepts deposits through third-party securities brokerage firms. The company offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through multiple channels, including online, print, and radio advertising. Synchrony Financial was incorporated in 2003 and is headquartered in Stamford, Connecticut. Synchrony Financial operates independently of GE Consumer Finance, Inc. as of November 17, 2015.

 

Stocks on the Move: Reynolds American Inc. (RAI), Amgen Inc. (AMGN), Royal Caribbean Cruises Ltd. (RCL)

Reynolds American Inc. (RAI) managed to rebound with the stock climbing 0.43% or $0.26 to close the day at $60.13 on active trading volume of 8.6M shares, compared to its three month average trading volume of 7.55M. The Winston-Salem North Carolina 27101 based company has been outperforming the cigarettes group over the past 52 weeks, with the stock gaining 24.53%, compared to the industry which has advanced 6.5% over the same period. With RSI of 80.25, the stock should still continue to rise and get closer to its one year target estimate of $57.01, making it a hold for now.

Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.

Amgen Inc. (AMGN) climbed 1.46% during last trading as the stock added $2.25 to finish the day at $156.68 with about 3.35M shares changing hands, compared to its three month average trading volume of 4M. The $116.56B market cap company, which fluctuated between $153.15 and $156.96 during the day, currently situated 18.03% above its 52 week low of $133.64 and -10.81% away from its one year high of $176.85. The RSI of 58.53 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Royal Caribbean Cruises Ltd. (RCL) saw its value decrease by -0.82% as the stock dropped $-0.77 to finish the day at a closing price of $93.63. The stock was lighter in trading and has fluctuated between $64.21-$96.09 per share for the past year. The shares, which traded within a range of $92.65 to $94.46 during the day, are up by 26.45% in the past three months and up by 31.93% over the past six months. It is currently trading 8.17% above its 20 day moving average and 10.96% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $98.33 a share over the next twelve months. The current relative strength index (RSI) reading is 71.77. The technical indicator do not lead us to believe the stock will see more gains any time soon.

Royal Caribbean Cruises Ltd. operates as a cruise company. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, Pullmantur, Azamara Club Cruises, CDF Croisières de France, and TUI Cruises brand names. The Royal Caribbean International brand provides cruise itineraries ranging from 2 to 24 nights with options for onboard dining, entertainment, and other onboard activities to various destinations. The Celebrity Cruises brand offers cruise itineraries ranging from 2 to 18 nights to various destinations; and operates onboard upscale ships that offer accommodations, fine dining, personalized services, and spa facilities. The Azamara Club Cruises brand offers cruise itineraries ranging from 3 to 20 nights that serve the up-market segment of the North American, the United Kingdom, and Australian markets. The Pullmantur brand provides cruise itineraries ranging from 2 to 15 nights with food and entertainment options for families and couples. The CDF Croisières de France brand offers seasonal itineraries to the Mediterranean, Europe, and Caribbean markets. The TUI Cruises brand provides onboard activities, services, shore excursions, and menu offerings for the German cruise market. As of December 31, 2015, the company operated 44 ships with itineraries ranging from 2 to 24 nights on approximately 490 destinations worldwide. Royal Caribbean Cruises Ltd. was founded in 1968 and is headquartered in Miami, Florida.

 

Stocks In Action: Amgen Inc. (AMGN), The Boeing Company (BA), Medtronic plc (MDT)

Amgen Inc. (AMGN) traded within a range of $152.76 to $157.5 after opening the day at $153.23. The company has seen its stock increase in value by 7.49% so far this year. The stock was up close to 2.73% on active volume in last trading session and closed at $157.16 per share. After the recent gain, the stock is currently holding -10.53% below its 52 week high of $176.85 and 18.39% above its 12-month low of $133.64. The shares are down by over -0.48% in the last three months, and the RSI indicator value of 60.81 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

The Boeing Company (BA) failed to extend gains with the stock declining -0.84% or $-1.42 to close the day at $167.7 on active trading volume of 4.88M shares, compared to its three month average trading volume of 3.34M. The Chicago Illinois 60606 based company has been outperforming the aerospace/defense products & services group over the past 52 weeks, with the stock gaining 46.91%, compared to the industry which has advanced 33.57% over the same period. With RSI of 73.26, the stock should still continue to rise and get closer to its one year target estimate of $168.75, making it a hold for now.

The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for various passenger and cargo requirements, as well as provides related support services to the commercial airline industry. This segment also offers aviation services support, aircraft modifications, spare parts, training, maintenance documents, and technical advice to commercial and government customers. The Boeing Military Aircraft segment is involved in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems for the global strike, vertical lift, and autonomous systems, as well as mobility, surveillance, and engagement. The Network & Space Systems segment engages in the research, development, production, and modification of electronics and information solutions; strategic missile and defense systems; space and intelligence systems; and space exploration products. The Global Services and Support segment offers integrated logistics, including supply chain management and engineering support; maintenance, modification, and upgrades for aircraft; and training systems and government services, such as pilot and maintenance training. The Boeing Capital segment facilitates, arranges, structures, and provides financing solutions, such as equipment under operating leases, finance leases, notes and other receivables, assets held for sale or re-lease, and investments. The Boeing Company was founded in 1916 and is headquartered in Chicago, Illinois.

Medtronic plc (MDT) gained $0.91 to close the day at a new closing price of $74.95, a 1.23% increase in value from its previous closing price that moved the stock 8.07% above its 52 week low of $69.35. A total of 4.88M shares exchanged hands during the day compared with its three month average trading volume of 7.03M. The stock, which fluctuated between $74.47 and $75.23 during the day, currently situated -15.54% below its 52 week high. The stock is up by 4.43% in the past one month and down by -7.05% over the past three months. With a one year target estimate of $84.54 and RSI of 57.39, the stock still has upside potential, making it a hold for now.

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

 

Stocks in the Spotlight: CBS Corporation (CBS), Amgen Inc. (AMGN), Lennar Corporation (LEN)

CBS Corporation (CBS) had a light trading with around 3.5M shares changing hands compared to its three month average trading volume of 4.34M. The stock traded between $62.69 and $63.89 before closing at the price of $63 with 0.03% change on the day. The New York New York 10019 based company is currently trading 54.19% above its 52 week low of $41.36 and -5.8% below its 52 week high of $66.88. Both the RSI indicator and target price of 49.84 and $67.38 respectively, lead us to believe that it should be put on hold over the coming weeks.

CBS Corporation operates as a mass media company worldwide. The company’s Entertainment segment distributes a schedule of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and distributes programming, including series, specials, news, and public affairs; operates online content networks for information and entertainment; and produces, acquires, and distributes theatrical motion pictures. Its Cable Networks segment offers subscription program services, such as original series, theatrical feature films, documentaries, boxing and other sports-related programming, and special events; and owns and operates multiplexed channels. This segment also owns and manages Smithsonian Networks, which operates a channel featuring cultural, historical, scientific, and educational programs; and operates a CBS Sports Network, a 24-hour cable program service that provides college sports and related content. The company’s Publishing segment publishes and distributes adult and children’s consumer books in printed, digital, and audio formats; and develops special imprints and publishes titles based on the products, as well as that of third parties and distributes products for other publishers. This segment also delivers content; and promotes its products on its Websites, social media, and general Internet sites, as well as those related to individual titles. Its Local Broadcasting segment owns 30 broadcast television stations; owns and operates 117 radio stations in 26 U.S. markets and related online properties; and operates local digital properties in various U.S. markets that combine the company’s television and radio local media brands online to offer the latest news, traffic, weather, and sports information, as well as local discounts, directories, and reviews for local community. The company was founded in 1986 and is headquartered in New York, New York. CBS Corporation is a subsidiary of National Amusements, Inc.

Amgen Inc. (AMGN) managed to rebound with the stock climbing 1.48% or $2.25 to close the day at $154.1 on light trading volume of 3.48M shares, compared to its three month average trading volume of 4.19M. The Thousand Oaks California 91320 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 2.85%, compared to the industry which has advanced 2.66% over the same period. With RSI of 55.08, the stock should still continue to rise and get closer to its one year target estimate of $181.73, making it a hold for now.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Lennar Corporation (LEN) shares were up in last trading by 1.21% to $46.93. It experienced higher than average volume on day. The stock increased in value by almost 5.94% over the past week and grew 9.34% in the past month. It is currently trading 7.73% above its 50 day moving average and 4.67% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.29% decrease in value from its one year high of $49.6. The RSI indicator value of 70.42, lead us to believe that it may reverse gains in the near term.

Lennar Corporation, together with its subsidiaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Lennar Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily include the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, as well as the purchase, development, and sale of residential land. The company also offers real estate related financial services, including mortgage financing, title insurance, and closing services for home buyers and others, as well as personal lines, property, and casualty insurance products. In addition, it is involved in raising, investing, and managing third party capital; and originating and selling into securitizations commercial mortgage loans, as well as investing in real estate related mortgage loans, properties, and related securities. Further, the company sponsors, invests, and manages private equity vehicles, and provides asset management and other services to the vehicles and other third parties. Additionally, the company develops multifamily rental properties. Lennar Corporation was founded in 1954 and is based in Miami, Florida.

 

3 Trending Stocks: Amgen Inc. (AMGN), Danaher Corporation (DHR), LKQ Corporation (LKQ)

Amgen Inc. (AMGN) continued its downward trend with the stock declining -0.57% or $-0.87 to close the day at $151.85 on light trading volume of 3.03M shares, compared to its three month average trading volume of 4.19M. The Thousand Oaks California 91320 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 1.58%, compared to the industry which has advanced 1.12% over the same period. With RSI of 49.69, the stock should still continue to rise and get closer to its one year target estimate of $181.73, making it a hold for now.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Danaher Corporation (DHR) climbed 0.04% during last trading as the stock added $0.03 to finish the day at $80.03 with about 3.01M shares changing hands, compared to its three month average trading volume of 3.29M. The $55.4B market cap company, which fluctuated between $78.97 and $80.44 during the day, currently situated 30.77% above its 52 week low of $62.82 and -2.85% away from its one year high of $82.64. The RSI of 51.8 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. Its Test & Measurement segment provides instruments products; services and products that help to convert concepts into finished products; professional tools; and wheel service equipment. The company’s Environmental segment provides instrumentation and disinfection systems; and solutions and services focused on fuel dispensing, remote fuel management, point-of-sale and payment system, environmental compliance, vehicle tracking, and fleet management. Its Life Sciences & Diagnostics segment offers chemistry systems, immunoassay systems, hematology and flow cytometry products, microbiology systems, and systems and workflow automations solutions. This segment also provides professional microscopes; mass spectrometers; bioanalytical measurement systems; workflow instruments and consumables; and filtration products, which are used to remove solid, liquid, and gaseous contaminants. The company’s Dental segment offers consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. The company’s Industrial Technologies segment provides equipment, consumables, and software for various printing, marking, coding, packaging, design, and color management applications; and a range of electromechanical and electronic motion control products. This segment also offers devices that sense, monitor and control operational or manufacturing variables; instruments, controls, and monitoring systems used in electric utilities and industrial facilities; engineered energetic materials components; and supplemental braking systems for commercial vehicles. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

LKQ Corporation (LKQ) saw its value decrease by -0.57% as the stock dropped $-0.18 to finish the day at a closing price of $31.48. The stock was higher in trading and has fluctuated between $23.95-$36.35 per share for the past year. The shares, which traded within a range of $31.46 to $31.88 during the day, are down by -4.23% in the past three months and down by -6.37% over the past six months. It is currently trading 0.56% above its 20 day moving average and -2.23% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $38.91 a share over the next twelve months. The current relative strength index (RSI) reading is 46.32. The technical indicator lead us to believe there will be no major movement any time soon, hold.

LKQ Corporation, together with its subsidiaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, and internationally. It operates in five segments: Wholesale – North America; Europe; Specialty; Glass; and Self Service. The company distributes various products, including aftermarket collision and mechanical products; recycled collision and mechanical products; and refurbished collision products, including wheels, bumper covers and lights, and remanufactured engines. It also offers recycled products, such as engines, transmissions, and door assemblies; sheet metal products comprising trunk lids, fenders and hoods, lights, and bumper assemblies; and refurbish products consisting of wheels, lights, plastic bumpers, and chrome bumpers, as well as heavy-duty truck products. In addition, the company sells scrap metal and other materials to recyclers; and extracts and sells the precious metals contained in various of recycled parts, such as catalytic converters. Further, it sells parts from older cars and light-duty trucks directly to consumers; and operates self service retail facilities that sell recycled automotive products from end-of-life-vehicles under the LKQ Pick Your Part name. Additionally, the company distributes and markets trucks and off-roads; speed and performance, and towing equipment and accessories; recreational vehicles; wheels, tires, and performance handling products; and miscellaneous accessories. It also manufactures and distributes automotive glass products; and distributes specialty vehicle aftermarket products and accessories. It primarily serves collision and mechanical repair shops, new and used car dealerships, metal recyclers, and specialty vehicle retailers and equipment installers, as well as retail customers. The company was founded in 1998 and is headquartered in Chicago, Illinois.

 

Eye Catching Stocks: HCP, Inc. (HCP), Amgen Inc. (AMGN), Alphabet Inc. (GOOGL)

HCP, Inc. (HCP) continued its upward trend with the stock climbing 0.86% or $0.26 to close the day at $30.33 on light trading volume of 2.46M shares, compared to its three month average trading volume of 4.41M. The Irvine California 92614 based company has been underperforming the reit – healthcare facilities group over the past 52 weeks, with the stock losing -4.39%, compared to the industry which has advanced 10.99% over the same period. With RSI of 54.04, the stock should still continue to rise and get closer to its one year target estimate of $30.23, making it a hold for now.

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Irvine, California with additional office in Nashville and San Francisco.

Amgen Inc. (AMGN) fell -1.26% during last trading as the stock lost $-1.95 to finish the day at $152.72 with about 2.46M shares changing hands, compared to its three month average trading volume of 4.2M. The $114.08B market cap company, which fluctuated between $152.4 and $154.55 during the day, currently situated 15.05% above its 52 week low of $133.64 and -13.06% away from its one year high of $176.85. The RSI of 51.56 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy’s Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Alphabet Inc. (GOOGL) saw its value increase by 1.96% as the stock gained $16.26 to finish the day at a closing price of $844.43. The stock was higher in trading and has fluctuated between $672.66-$845.54 per share for the past year. The shares, which traded within a range of $828.7 to $845.54 during the day, are up by 2.77% in the past three months and up by 11.21% over the past six months. It is currently trading 3.32% above its 20 day moving average and 5.45% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $965.81 a share over the next twelve months. The current relative strength index (RSI) reading is 70.22. The technical indicator do not lead us to believe the stock will see more gains any time soon.

Alphabet Inc., through its subsidiaries, provides online advertising services in the United States, the United Kingdom, and rest of the world. The company offers performance and brand advertising services. It operates through Google and Other Bets segments. The Google segment includes principal Internet products, such as Search, Ads, Commerce, Maps, YouTube, Apps, Cloud, Android, Chrome, and Google Play, as well as technical infrastructure and newer efforts, such as Virtual Reality. This segment also sells hardware products comprising Chromecast, Chromebooks, and Nexus. The Other Bets segment includes businesses, such as Access/Google Fiber, Calico, Nest, Verily, GV, Google Capital, X, and other initiatives. Alphabet Inc. was founded in 1998 and is headquartered in Mountain View, California.